This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00092742
First received: September 23, 2004
Last updated: June 29, 2015
Last verified: June 2015
September 23, 2004
June 29, 2015
February 2003
December 2005   (Final data collection date for primary outcome measure)
Discontinuations due to clinical and laboratory gastrointestinal adverse experiences
Not Provided
Complete list of historical versions of study NCT00092742 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
The duration of treatment is 12 months.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: MK0663, etoricoxib
  • Drug: Comparator: Diclofenac sodium
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4086
December 2005
December 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females 50 years or older with rheumatoid arthritis.

Exclusion Criteria:

  • History of gastrointestinal malabsorption or inflammatory bowel disease
  • History of heart problems such as: congestive heart failure (CHF), heart attack or high blood pressure.
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00092742
0663-072
2004_055
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP